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Older Adults with Intellectual Disability 
 
Abstract 
Purpose of review: Improvements in health and social care for people with intellectual 
disability have led to a dramatic increase in the life expectancy of this population, resulting 
in a large and growing number of older adults with intellectual disability. They are at risk of 
age-related mental disorders such as dementia, and continue to present with high rates of 
mental illness.    
Recent findings: Recent research with older adults with intellectual disability has included 
physical health issues that may affect mental well-being, and biological and clinical features 
of dementia in people with Down syndrome. Two key clinical trials, of memantine and anti-
oxidants for dementia in Down syndrome showed that these treatment options were 
ineffective in the short term. Other research focused on environmental and psychosocial 
issues (including carer issues) and end of life care.  
Summary: Improved mental well-being requires effective management of mental illness and 
co-morbid physical health problems as well as consideration of environmental and social 
issues. Biological research has identified potential treatments for age-related decline which 
has lead to development of medication trials.  Despite disappointing results, two recent 
medication trials showed that randomised controlled trials are feasible in older people with 
intellectual disabilities - a group who are often excluded from trials.  
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Introduction 
Improvements in health and social care for people with intellectual disability have led to a 
dramatic increase in the life expectancy of this population, which is resulting in a large and 
growing number of older adults with intellectual disability. This has been particularly striking 
in the Down syndrome population – the population of people with Down syndrome over 40 
years old has doubled in Northern European countries since 1990 [1**], while the mean life 
expectancy of people with intellectual disability of any cause in the 1930s was estimated at 
18.5 years, which increased to 66 years in the 1990s [2].  
Older adults are at risk of age-related disorders, and people with intellectual disability may 
be particularly challenged by declines in health, symptoms such as pain [3] and increased 
dependency. Cognitive decline further reduces a person’s ability to cope and adapt.  
This review will consider recent research (August 2010 - March 2012) on mental disorders in 
people with intellectual disability, including biological, health and psychosocial factors, its 
impact on carers and care systems, and advances in treatment options.   
 
Epidemiology of mental disorders in older adults with intellectual disability 
The prevalence of many mental health problems remains relatively stable as people age [4], 
regardless of whether they have co-morbid autism [5]. However, prevalence of depression 
was found to be significantly higher among older adults with intellectual and other 
developmental disabilities (aged 55 and over) in Canada compared to matched peers from 
the general population [6], while problem behaviours tend to decrease with age [4]. Mental 
illness adds significantly to carer burden [7] and has a significant independent relationship 
with cost of care in older adults with intellectual disability [8].  
Rates of dementia in the population with intellectual disability not due to Down syndrome 
are comparable to or higher than the general population, while Alzheimer’s disease in 
people with Down syndrome increases from under 10% in their 40s to more than 30% in 
their 50s, with some studies reporting prevalence rates in excess of 50% for those 60 and 
older (see Strydom et al 2010 [9] for a review). Dementia may be diagnosed four times more 
often in older people with intellectual and other developmental disabilities than in the 
general population [6].  
 
Physical health in older adults with intellectual disability 
Physical health problems are often linked with poorer mental health. There have been 
several recent studies of the physical health issues of older people with an intellectual 
disability. These studies indicate that functional restrictions, multi-morbidity, an unhealthy 
lifestyle, limited detection of risk factors for cardiovascular disease, limited participation in 
screening programmes and missed diagnoses due to a lack of subjective complaints are all 
significant factors in this population [10].   
A Dutch cross-sectional study of people with intellectual disability aged 50 and over living in 
a variety of settings showed a higher prevalence of obesity than in the general older Dutch 
population. Use of atypical antipsychotic medication was significantly associated with being 
overweight or obese, along with physical inactivity, being female, having Down syndrome, 
being older, having less severe intellectual disability, autism, and higher independency in 
terms of preparing meals  [11*]. 
People with Down syndrome experience premature ageing including cataracts [12] and 
presbycusis [13], which could impact on their function and mental state. The pattern of 
physical health issues associated with Down syndrome changes as they age - a recent 
Finnish population based study of case records of people with Down’s syndrome [14] found 
that congenital heart defects and middle ear infections were mostly experienced by younger 
people, while thyroid disease, epilepsy, and Alzheimer's disease were frequent among older 
people. Women with Down syndrome often experience early menopause, which has been 
associated with an increased risk of dementia and decreased life expectation [15**].  
The European POMONA II study [16**] focussed on age-specific differences relating to 
environment and lifestyle factors and on the prevalence of specific medical conditions in 
people with intellectual disability. It showed that rates of smoking and use of alcohol were 
lower than in the general population but were higher with older age. Over 60% of older 
adults had a sedentary lifestyle. Cataract, hearing disorder, diabetes, hypertension, 
osteoarthritis/arthrosis, and osteoporosis were positively associated with increasing age, 
while allergies and epilepsy were negatively associated. Furthermore, some evidence of 
health disparities was found for older people with intellectual disability, particularly in terms 
of underdiagnosed or inadequately managed preventable health conditions.  
 
Dementia 
Recent publications from the USA [17] and Britain [18] provide important guidelines on 
dementia in people with intellectual disabilities. Diagnosis of dementia is often difficult in 
people with pre-existing cognitive deficits, and it is therefore important to establish the 
validity of diagnostic criteria in older adults with intellectual disability. ICD10 and DSM IV 
dementia criteria both showed substantial reliability and satisfactory validity, although 
caution is advised when using these criteria in people with more severe intellectual 
disability and/or co-morbid sensory disabilities [19*].  
Most of the recent research in dementia in people with intellectual disability has focused on 
Down syndrome and it is hoped that by understanding of the pathophysiology of dementia 
in this population, it will also further the understanding of dementia in the general 
population.  
Some recent research on clinical features of dementia in people with Down syndrome has 
focussed on pre-clinical dementia or the early stages of dementia in this population. In a 
longitudinal study of 30 adults with Down syndrome, individuals with cognitive 
deterioration showed significant changes in behaviour and decreases in executive function 
measures when compared to the group with no cognitive deterioration during the study 
period [20]. The authors highlight that specific behavioural changes can be seen even in the 
early stages of cognitive deterioration, which is in keeping with the findings of another study 
of adults with Down syndrome without a diagnosis of Alzheimer’s disease (n = 78), which 
identified early onset of disinhibited behaviours in a large proportion [21]. The authors 
hypothesised that the high rates of disinhibition in the preclinical stages of dementia in 
people with Down syndrome may reflect a disproportionately affected orbito-frontal circuit, 
which is mediated by serotonin. Further research would be important to confirm this. 
The amyloid cascade hypothesis remains the most prominent theory for the 
pathophysiology of Alzheimer’s disease and is of much interest in Down syndrome, as the 
APP gene on chromosome 21 is strongly implicated in the development of Alzheimer’s 
neuropathology in these patients. Recent advances in Positron Emission Tomography (PET) 
imaging using new ligands have enabled researchers to show cerebral amyloid and tau in 
people with Down syndrome. In a proof-of-principle study, a marker of cerebral amyloid-β 
(11-labelled Pittsburgh Compound B, [11C] PiB) was found to have significant binding in 
people with Down syndrome who were older than 45 years, whether or not they had clinical 
features of dementia [22**] and shows that [11C] PiB PET can be successfully used in this 
population. In another PET study, [18F] FDDNP (a ligand that detects both amyloid and tau) 
has been shown to have high binding levels in adults with Down syndrome, which (in some 
brain regions) was correlated to age and behavioural dysfunction and comparable to 
findings in participants with Alzheimer’s disease from the general population [23**]. 
The relationship between amyloid-β levels in plasma and cognitive functioning in adults with 
Down syndrome has also been explored - plasma amyloid-β levels did not dissociate 
between adults with Down syndrome with and without dementia, but ApoE4 was associated 
with higher levels of amyloid-β 40 but not amyloid-β 42 in those with dementia [24]. 
Although biomarkers are being considered for the diagnosis of Alzheimer’s disease [25], the 
clinical application of plasma amyloid-β and amyloid or tau PET scans is yet to be 
established. 
Improved understanding of the neurobiology of Down syndrome is now leading to potential 
treatment options for improving cognitive functioning or modifying the dementia process in 
people with Down syndrome. For example, Down syndrome mouse model studies showed 
that NMDA receptor signalling is defective in Down syndrome, which is associated with 
impaired hippocampal function. Treatment of Down syndrome mice with memantine (a N-
methyl-D-aspartate (NMDA) receptor antagonist that improves cognitive function in older 
adults with moderate-to-severe Alzheimer’s disease in the general population) resulted in 
improved learning and memory (see Costa for a review [26]). This observation has led to 
several trials of memantine in Down syndrome.   
The MEADOWS trial was a 52-week double blind, randomised, placebo controlled trial of 
memantine in 173 people with Down syndrome with and without dementia [27**]. Both 
groups showed reductions in function and cognition over the course of the study, but there 
were no differences between the groups for any of the outcomes.  
Oxidative stress is also thought to play a role in the pathophysiology of Alzheimer’s disease 
and is particularly of interest in Down syndrome, as the dosage sensitive superoxide 
dismutase gene (SOD1) is located on chromosome 21.  Oxidative stress in people with Down 
syndrome and the potential for antioxidant supplements is explored further in two recent 
review articles [28, 29]. A two year randomised controlled trial of antioxidant 
supplementation (900IU alpha-tocopherol, 200mg ascorbic acid and 600mg alpha-lipoic 
acid)  in people with Down syndrome and dementia was conducted by Lott et al [30**]. 
Their findings were similar to studies of antioxidants in people with Alzheimer’s disease in 
the general population, as participants receiving antioxidant supplements did not show an 
improvement in cognitive function or stabilisation of cognitive deterioration when 
compared to the placebo group. 
 
Social and environmental issues  
Appropriate social care and support and a comfortable and suitable living environment is 
conducive to good mental health. This link between social and environmental issues and 
mental health is highlighted in an important recent study from the Netherlands, which 
studied the association between life events and symptoms of anxiety and depression in 
older adults with intellectual disability [31**]. Depression and anxiety were assessed using 
self-report and informant-report screening instruments (n = 988) and psychiatric interviews 
(n = 286), and 72% of participants had been exposed to one or more negative life events in 
the preceding year. Minor physical illness or injury and problems with fellow residents were 
found to be significantly associated with both increased depressive and anxiety symptoms. 
Decline or loss of mobility and loss of leisure-time activities were both found to be 
significantly associated with depressive symptoms, but causality cannot be assumed, as the 
study design is cross-sectional.  
The benefits of daytime activities and community based services for older adults with 
disabilities, including those with intellectual disabilities, presents as a common theme in two 
qualitative studies based in Scotland [32] and Australia [33] respectively.  In Norway, where 
senior centres are visited by approximately 40-50% of the population aged 67 years or older, 
participants without intellectual disabilities who attended these centres considered the 
potential barriers and solutions to inclusion of people with intellectual disability [34]. 
Barriers included attitude towards intellectual disability and personal, organisational and 
economic issues. Suggested solutions included financing the centres so that appropriate 
support could be provided for individuals with intellectual disability. 
Several studies have considered the issues of access to support and housing associated with 
ageing with an intellectual disability. One qualitative study from Australia conducted focus 
groups and individual interviews with 15 people with intellectual disability and 10 family 
carers. Themes that emerged included the issues associated with transition from informal to 
formal housing and support services. The majority of family members interviewed were 
concerned that the residential aged care sector would struggle to meet the needs of older 
people with intellectual disabilities, who were often younger than the usual resident [35], 
while a cross-sectional study in Taiwan found that more than half of managers of 
institutions that care for people with intellectual disabilities were not satisfied with their 
provisional care of ageing residents with intellectual disability [36].  
Specific issues related to supporting people with Down syndrome and advanced dementia 
are highlighted in a qualitative study which involved focus groups of staff working in six 
intellectual disabilities services and a palliative care service in Ireland. Readiness to respond 
to end of life needs, fear of swallowing difficulties and environmental concerns and ageing 
in place were common themes [37].  
A  proposed quality measurement framework in group home dementia care for people with 
intellectual disabilities [38] included: 1. Clinically relevant and early periodic assessment, 2. 
Functional modifications in the long-term setting, 3. Constructive staff education and 
functionality for stage-adapted care, and 4. Flexible long term service provision that 
recognises and plans for the progression of decline and loss of function. 
 
Carer issues  
Family carers play an important – frequently the most important – role in supporting people 
with intellectual disability. As individuals with intellectual disability grow older, so do their 
family carers. This may bring with it a change in the needs of the carer and a change in their 
abilities to care for their loved ones (in particular, due to physical limitations). 
Two recent studies have examined factors that may be important in older carers of adults 
with intellectual disability. One large study, based in Taiwan, interviewed 350 female carers 
aged 55 years and over. Rates of self-reported depressive symptoms in these carers were 
high, and were significantly associated with self-reported carer physical health, caregiver 
burden and lack of social support [39*]. 
An Australian study found the caring role may be rewarding as well as stressful - highlighting 
the importance of recognising both the benefits and burdens of caring [40].  
 
End of life issues 
Age related medical conditions such as late onset seizures, pneumonia, fractures and other 
emerging medical problems - many requiring hospitalisation - have been found to be 
significant events for adults with Down syndrome which can contribute to their decline in 
health status and adaptive functioning [41]. 
Ageing adults with Down syndrome experienced more relocations and other life events than 
adults with intellectual disabilities aged 50 and older without Down syndrome [42]. Age 
related functional decline and the higher incidence of dementia were implicated as the 
contributing factors that lead to relocation and nursing home placement. Mortality was 
significantly earlier in the Down syndrome group with the mean age at death to be 61.4 
years compared with 73.2 years in those without Down syndrome. 
The end of life care and treatment of people with an intellectual disability is likely to vary. 
End-of-life care policies in Flemish residential care facilities were found to be often absent 
and their content was not very specific for people with intellectual disability [43].  Although 
some had a policy on palliative care, it appeared that end-of-life decisions with a possible 
life-shortening effect were rarely mentioned and elaborated on.  
People with intellectual disability may have only partial understanding of the concept of 
death, leaving them vulnerable to misinterpretations. There is scope for making sense of 
death by using religious and spiritual themes and by providing teaching on the biological 
explanations of the life cycle [44]. 
 
Conclusion 
Recent research with older adults with intellectual disability has focused on a number of 
different areas, including physical health issues, biological and clinical features of dementia 
in people with Down syndrome and psychosocial issues (including carer issues). Potential 
treatments for cognitive decline have been identified using basic sciences research, for 
example using Down syndrome mouse models, which is now being translated into humans 
and has lead to development of medication trials in people with Down syndrome. The 
recent memantine and antioxidant trails in older adults with Down syndrome highlight that 
randomised controlled trials are feasible in older people with intellectual disabilities - a 
group who are often excluded from clinical trials.   
Future research should build on our increasing understanding of the neurobiology of 
intellectual disabilities and ageing associated mental disorders, while pursuing potential 
treatment options in clinical trials. Effective care environments and interventions to reduce 
carer burden are equally important topics, as is exploring ways to improve end-of-life care.   
 
Key Points 
 Mental health issues and  dementia are common in older adults with intellectual 
disability 
 Recent research has included physical health issues that may affect mental well-
being, biological and clinical features of dementia in people with Down syndrome 
and psychosocial issues, including carer issues.  
 The recent memantine and antioxidant trails in older adults with Down syndrome 
highlight that randomised controlled trials are feasible in older people with 
intellectual disabilities. 
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